Gene expression profiles of BM CD34-derived megakaryocytic cells (MKs) were compared in patients with essential thrombocythemia (ET) and healthy subjects utilizing oligonucleotide microarray analysis to identify differentially expressed genes and disease-specific transcripts.
Introduction
Essential thrombocythemia (ET) is a malignant MK disorder principally characterized by abnormal proliferation of a malignant MK clone and persistent thrombocytosis [1] [2] [3] . ET is usually associated with elevated numbers of bone marrow (BM) MKs and of morphologically and functionally abnormal circulating platelets 1, 4, 5 . ET-affected BM displays enlarged and mature MKs with hyperploid nuclei 6 . Even though ET is usually considered to be a clonal disease, it has recently been suggested that some patients do not have a clonal disorder 7 , this issue is further complicated by the recent observation of monoclonal hematopoiesis in normal elderly women 8 .The molecular events underlying the commitment and differentiation of normal and malignant megakaryocytes are poorly understood [9] [10] [11] [12] [13] .
The cause of ET is unknown. It is thought that molecular lesions in critical genes regulate the balance between proliferation/differentiation and apoptosis of MK progenitors. The few reported consistent cytogenetic abnormalities 14 include trisomies of chromosomes 8 and 9
and deletions in 13q and 20q 15, 16 . Since little is known about specific molecular abnormalities, further molecular and transcriptional studies are required to better elucidate the development of the malignant MKs.
We utilized microarray technology to study the malignant megakaryocytopoiesis of ET. In particular, CD34+ hematopoietic progenitor cells taken from the BM of ET patients and healthy subjects were induced to differentiate along the megakaryocytic lineage in liquid suspension cultures by continuous addition of 100ng/mL of thrombopoietin. The pattern of gene expression identified in normal CD34-derived MKs was compared with that of ET CD34-derived MKs to identify differentially expressed genes and disease-specific transcripts.
We found that expression of genes involved in the apoptotic pathway is impaired in ET CD34-derived MKs. Moreover, CD34-derived MKs of ET patients were more resistant to apoptosis than their normal counterparts.
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Patients
Routinely collected BM and peripheral blood (PB) samples from 15 patients (9 males, 6 females; median age, 43 yr, range 24-66 yr) with ET diagnosed according to PVSG criteria 17 were studied. The median platelet count was 1098x10 9 /L (range 810-1832). Karyotype analysis did not show any chromosome aberrations. At the time of the study no patient showed hemorrhagic or thrombotic complications. The patients were either newly diagnosed (n=8) or off cytotoxic treatment for at least 3 months (n=7). BM samples from 15 healthy donors were used as controls. All subjects (patients/controls) provided written informed consent for the study, which was performed in accordance with the Helsinki declaration of 1975. In line with national and European Union guidelines, ethical approval was not required for this study.
Purification of CD34+ cells
Mononuclear cells were isolated from BM (20-30ml) by Ficoll-Hypaque (D=1.077g/mL; Pharmacia, Uppsala, Sweden), rinsed and adherence-depleted overnight. After recovery of suspended cells, CD34+ cells were isolated using a magnetic cell-sorting program (Mini-MACS, Miltenyi Biotec, Auburn, CA) and the CD34 isolation kit in accordance with the manufacturer's recommendations. The purity of CD34-selected cells was determined for each selection as previously described 18 , and the percentage of CD34+ cells ranged from 89% to 98%.
Liquid suspension cultures and purification of CD34-derived MKs
CD34+ cells (from 12 patients and 12 controls) were differentiated in thrombopoietin-treated liquid suspension cultures as previously described 19 . Briefly, CD34+ cells (80,000/mL) were resuspended in a serum-free medium in the presence of 100 ng/mL of human recombinant 19 . The purity of the MKs was determined for each isolation by indirect immunofluorescence, using an anti-CD41b
MoAb which reacts with a different epitope of the IIb -3 subunit (Immunotech Inc., Westbrook, ME), followed by a goat anti-mouse IgG, covalently linked to fluorescein (Becton Dickinson, San Jose, CA).
In a second set of experiments, CD34+ cells (from 3 patients and 3 healthy subjects) were also cultured in a serum-free medium with various concentrations of TPO (0.1, 1, 10, 100 ng/mL) for 14 days.
Microarray set up and analysis
Total cellular RNA was isolated from four CD34-derived MK pools (from two groups of 6 patients and two groups of 6 healthy subjects) using the guanidinium-cesium chloride centrifugation technique 20 , with slight modifications. RNA was assessed by formaldehyde agarose gel electrophoresis and quantified by UV absorbance. Biotin-labeled target synthesis reactions were performed using standard protocols supplied by the manufacturer (Affymetrix, Santa Clara, CA). Briefly, 5 µg of the RNA was converted into double-stranded cDNA by reverse transcription using a cDNA synthesis kit (SuperScript Double-Stranded cDNA Synthesis, Invitrogen, Paisley, UK), following the protocol supplied by the manufacturer, with a T7-(dT) 24 primer (Affymetrix, Santa Clara, CA). After the second-strand synthesis, labeled cRNA was generated from the purified cDNA sample (Gene Chip Sample CTP and biotin-16-UTP, as described by the manufacturer. The labeled cRNA was purified using the provided Affymetrix spin columns. The concentration of biotin-labeled cRNA was determined by UV absorbance. In all cases, 15 µg of each biotinylated cRNA preparation was fragmented, assessed by gel electrophoresis, and put in the hybridization cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre), as recommended by the Affymetrix protocol. Samples were hybridized to an identical lot of Affymetrix HG-U133A GeneChip arrays for 16 h. GeneChips were washed and stained following the instrument's standard Eukaryotic GE WS2v4 protocol and using antibodymediated signal amplification as already described 21 .
The images from the scanned chips were processed by means of Affymetrix Microarray Analysis Suite 5.0 (MAS 5.0). The amount of a transcript mRNA, i.e. the expression level (signal), was determined with the MAS 5.0 absolute analysis algorithm 22 , as well as the presence or the absence of a transcript. The MAS 5.0 comparison analysis algorithm was used to compare gene expression levels between four samples and to evaluate change in the expression level of a transcript: increase; decrease or no change and the fold change in transcript expression levels, expressed as the log 2 ratio (signal log ratio; a log 2 ratio of 1 is equal to a fold change of 2). All expression values for the genes in the absolute and comparison analysis were determined using the MAS 5.0 global scaling option. The MAS 5.0 generated absolute and comparison analysis data were then uploaded onto Affymetrix Micro DB 3.0 database and processed with Affymetrix Data Mining Tool (DMT) 3.0 software. DMT 3.0 was used to query, filter, and to sort data from data sets. The gene lists created by DMT software were transferred to Microsoft Excel and linked to the Internet genome databases (i.e. NetAffx, GenBank, Swiss Prot, OMIM, and GeneCards) and also uploaded onto Affymetrix Gene Ontology Mining Tool, which in addiction to providing the Gene Ontology 
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Results

Characterization of the cultured MKs
To characterize MK maturation, CD34+ BM cells from healthy or ET patients were cultured in serum-free medium in the presence of TPO. MK differentiation was assessed by light microscopy evaluation after May-Grunwald Giemsa staining, and by analysis of IIb 3 expression with a CD41a MoAb and flow-cytometry. At morphological analysis after 14-16 days of culture, different degrees of maturation were observable with small mononucleated megakaryoblasts appearing alongside fully developed MKs ( Figure 1A ). The MK maturation was confirmed by the high frequency (92%-96%) of IIb 3+ cells in both patients and healthy subjects ( Figure 1B ). Morphological analysis of purified MKs is shown in Figure 1C .
Note the presence of small megakaryoblasts near mature MKs.
Microarray data
Gene expression analysis. We profiled gene expression of the two CD34-derived MK pools from healthy subjects and the two pools from ET patients using Affymetrix HG-U133A GeneChip array, which covers about 22,200 transcripts of known genes. All these data have been deposited in the Gene Expression Omnibus public database, at http://www.ncbi.nlm.nih.gov/geo (accession numbers are GSM8649 and GSM15648 for healthy subjects; GSM8650 and GSM15650 for ET patients; GSE567 and GSE997 for comparisons of ET MKs vs normal MKs).
The complexity of the mRNAs was rather similar in the normal and malignant MKs, with about 10,000 genes (almost 50%) being expressed in each setting. Excluding the lowabundance transcripts (signal <100), the ET MK pools expressed 4637 genes and the normal pools expressed 4655. To identify genes that were differentially expressed in the two populations, we compared their expression profiles using the Affymetrix comparison analysis algorithm, which distinguished in the malignant MK pools those genes whose expression was 'Increased', 'Not Changed' and 'Decreased'. We performed pair-wise comparisons of individual genes and of their expression changes in ET MKs with respect to normal MKs. Figure 2 reports the numbers of genes that were specific to either the normal MKs (both pools) or the ET MKs (both pools), or that were expressed in the two pools of each population ('Increased', 'Decreased' and 'Not Changed').
GO Mining Tool functional analysis of differentially expressed genes. We uploaded onto the
NetAffx GO Mining Tool lists of those genes that were 'increased' (n=233) and 'decreased' (n=314) in ET MKs with respect to their normal counterpart. As can be seen from Table 1 , most of the 'Increased' genes are involved in the transcriptional process, and particularly in RNA metabolism and processing, apoptosis and cell-cycle regulation; their molecular functions include nucleic acid binding and RNA binding. By contrast, most of the 'Decreased' genes are involved in macromolecule and protein biosynthesis, and are structural constituents of ribosomes. A significant number of decreased genes were also addressed to the mitochondrial membrane, some of which play key roles in the induction of apoptosis ( Table 2 ). The latter include BAX, BNIP3, and BNIP3L (all Bcl2-associated), and members of the mitochondrial permeability transition (PT) pore complex, which plays a pivotal role in apoptosis.
Functional categorization of differentially expressed genes.
To shed further light on expression profile differences between ET and normal MKs, we divided the genes that were 'increased'/'decreased' in ET MKs into functional categories. Expression levels of comprehensive sets of the differentially expressed genes involved in apoptosis, cell-cycle regulation, and transcription are shown in Figure 3 A, B and C. None of the other categories thought to be likely candidates for association with the molecular pathology of ET-including growth factors, growth factors receptors, and tumor suppressors-contained 'increased'/'decreased' genes (data not shown).
Where possible, gene expression was confirmed by quantitative RT-PCR. As can be seen from Figure 3D , the expression levels of most of the analyzed genes were broadly similar to those observed in the microarray assay. Among the major apoptosis-related genes, BNIP3L
showed decreased expression both at quantitative RT-PCR and microarray analysis.
However, the significant decrease of BAX at microarray analysis was not confirmed at quantitative RT-PCR, where a slight increase was recorded.
Functional classification of the genes 'specific' to ET/normal MKs.
Those genes 'specific' to ET MKs (n=10) and to normal MKs (n=9) are listed according to their molecular function in Table 3 (functional clusters were not apparent for all the genes). Where possible, the expression patterns were also evaluated at quantitative RT-PCR. The results are consistent with array data (Table 3) .
Expression of genes involved in MK development.
We also analyzed expression levels of genes known to play a role in MK development (Table 4) . A wide range of signal intensity levels was recorded among the various genes in normal MKs. Notably, genes encoding for structural proteins like GPIB (glycoprotein Ib, alpha polypeptide), GPIIb (integrin alpha 2b) and CD9, which all play a pivotal role in MKs and platelet function, [24] [25] [26] [27] were highly expressed in normal MKs. As regards some essential regulators of distinct stages in MK differentiation, 13 NF-E2 (nuclear factor-erythroid 2) showed high expression levels, whereas GATA 1, FOG-1 (friend of GATA 1) and Fli-1 (friend leukemia virus integration 1) did not. The high expression of JUND, Mcl1 (myeloid cell leukemia sequence 1) and TAL-1 (T-cell acute lymphocytic leukemia 1) in normal MKs has never been described before. Genes encoding for the chemokine PF4 (platelet factor 4), PBP (pro-platelet basic protein) as well as the CXCR4 (chemokine receptor 4) were also highly expressed.
The SLRs indicate that the expression of the majority of the genes, listed in Table 4 , was not changed in malignant MKs with respect to their normal counterparts. Interestingly, only two genes showed increased expression in ET MKs, namely IL-8 (interleukin-8) and the GRO1 oncogene (bold in Table 4 ). Remarkably, expression of the TPO receptor gene (Mpl, myeloprolifarative leukemia virus oncogene), which is thought to be implicated in the pathogenesis of ET 1, 3 , remained unchanged in malignant MKs. Quantitative RT-PCR confirmed the array SLRs in the majority of the genes studied ( Table 4 ). Four of the 24 genes, namely ITGB3 (integrin, beta3), IL6R (interleukin 6 receptor), CXCR4 and MAPK14
(mitogen /activated protein kinase 14) turned out to be increased in RT-PCR but 'Not
Changed' in array analysis, since TaqMan analysis can show a greater dynamic range in testing differences in gene expression.
Gene profiling of normal platelets has already been studied 28 . We found that more than 90% of the reported top 50 platelet genes were also highly expressed both in normal and ET MKs, and showed similar levels of expression in the two cell populations (Supplementary Table   S1 ).
Protein analysis of selected genes
To further confirm the gene-profiling data and in order to investigate whether the expression of genes in MKs mirrors that found in platelets, we utilized flow cytometry to analyze expression of selected proteins in platelets from healthy subjects and ET patients. Protein analysis broadly confirmed the gene expression results. As regards de novo expressed genes, the CD14 protein was not expressed on the extracellular platelet membrane of either normal or ET platelets; however, low intracellular levels of CD14 were found in ET, but not normal, platelets ( Figure 4A ). To confirm this finding, we analyzed CD14 expression in a megakaryoblastic cell line (MK-1) 29 : this cell line markedly positive for CD14 with an intracellular distribution ( Figure 4B ). Among the differentially expressed genes, we analyzed protein levels of BAX and IGF1R because the former induces a proapoptotic signal 30 , while the latter is associated with an increased cell-survival signal in hematopoietic cells 31 . BAX protein expression was markedly reduced in ET platelets compared with their normal counterpart ( Figure 4C ), whereas IGF1R protein expression was increased ( Figure 4D ).
Characterization of apoptosis in normal and ET MKs
Since microarray analysis revealed impaired expression of genes involved in the regulation of the apoptotic pathway in ET MKs, we also performed functional assays to evaluate the biological consequences.
We first characterized apoptosis of normal and ET MKs in serum-free culture at 7, 14 and 21 days after stimulation with 100 ng/ml of TPO by means of both PI and Annexin V staining, as evaluated at flow cytometry ( Figure 5 ). The mean percentages of sub-G1-peak apoptosis after PI staining was significantly decreased in ET MKs with respect to normal cells, both To confirm these results, in parallel experiments, we assayed the effects of various concentrations of TPO (0.1, 1, 10, 100 ng/mL) on the apoptosis (Annexin-V staining) of normal and ET MKs after 7 and 14 days of liquid culture. As shown in Figure 6 , ET MKs showed markedly increased resistance to apoptosis with respect to their normal counterpart;
at all concentrations, the percentage of apoptotic MKs was greater in normal MKs. This Figure 6A ) and in more mature cells (day 14; Figure 6B ).
Discussion
Malignant megakaryocytopoiesis is the hallmark of ET. Numerous studies have characterized the in vitro growth of the malignant MK progenitors 32 , with spontaneous MK growth being observed in the majority of patients. This property does not appear to be due either to paracrine stimulation, as can be observed in limit dilutions 33 , or to autocrine stimulation by TPO 34 . Nevertheless, circulating MK progenitor cells from ET patients are hypersensitive in vitro to TPO 34 . Dysregulation of megakaryocytopoiesis in ET has been found to involve defective binding of TPO by platelets and MKs, due to reduced or abnormal MPL expression; this results in increased levels of plasma TPO and increased sensitivity of MKs to TPO, in turn leading to MK hyperproliferation 2, 12, 35, 36 . However, no mutations of the TPO gene have yet been identified in families with hereditary ET 37, 38 , and no mutations in the TPO receptor 39 have been found in patients with acquired ET. New approaches are needed to better elucidate the mechanisms of malignant megakaryocytopoiesis in ET. To our knowledge, the present study provides the first microarray-based comparison of the molecular phenotypes of CD34-derived MKs taken from malignant BM of ET patients and from healthy subjects.
Analysis of our microarray data reveals that the expression of certain genes involved in the apoptotic pathway is impaired in ET MKs (Tables 1 and 2 ). Activation of the apoptotic cell machinery in normal MKs is known to play a key role in MK development. Zauli et al. 40 showed that cultured MKs undergo apoptosis in vitro and that the terminal phase of the MK life span is characterized by onset of apoptosis. Subsequent reports close relationships between apoptosis, MK maturation and platelet release 41, 42 . However, no data have previously been reported on the mechanism of apoptosis in ET MKs.
In the present study, downregulation was apparent in genes with pro-apoptotic activity, such as BAX, BNIP3, BNIP3L and members of the mitochondrial PT pore complex-a composite channel that is involved in the regulation of mitochondrial membrane permeability during [43] [44] [45] . We also observed increased expression of the CFLAR (CASP8 and FADDlike apoptosis regulator), which exerts known anti-apoptotic activity 46 , along with reduced expression of LGALS1 (galectin 1), another pro-apoptotic factor 47 ( Figure 3 ). Moreover, IGF1R over-expression, which was also apparent in ET MKs, could play a role by deregulating the apoptotic process. IGF1R is over-expressed in most malignant tissues,
where it functions as an anti-apoptotic agent by enhancing cell survival 48 ( Figure 3 ).
Interestingly, we also found increased expression of SDF-1 (stromal cell-derived factor 1) in the malignant MKs (Table 4) Extension of these findings to in vivo megakaryocytopoiesis must be considered with particular caution. In fact, cytokines other than TPO and complex cell-cell and cell-BMmatrix interactions are known to play a primary role in the development of MKs in vivo.
However, Zauli et al. 40 found that primary megakaryocytic cells undergo apoptotic cell death in culture more rapidly than CD34-derived MKs. Furthermore, there is increasing evidence that chronic myeloproliferative diseases are associated with perturbed apoptotic programs We also performed a subanalysis of genes that are known to be involved in megakayocytopoiesis 54 . As expected, the majority of these genes were expressed at high levels in both normal and malignant MKs. Recent advances have highlighted the particular importance of four transcriptional regulators-GATA-1, FOG-1, NF-E2 and Fli-1 (Friend leukemia virus integration 1)-in distinct stages of MK commitment and differentiation 13 . However, our gene profiling analysis did not reveal significant differences in expression between normal and ET MKs for any of these four genes (Table 4) . By contrast, we found over-expression of the JunB proto-oncogene and RUNX1 (runt-related transcription factor 1) in ET MKs. Up-regulation of JunB in ET MKs could be particularly interesting since evidence exists that the related genes, c-Jun and c-Fos, are strongly expressed by developing MKs 55, 56 , while in chickens v-Jun and v-ErbB cooperate in induction of transformation of normal BM progenitors into leukemic megakaryoblasts 57 . As regards RUNX1, recent data suggest that this myeloid transcription factor is expressed in MKs, where it cooperates with GATA1 in MK commitment and differentiation 58 , and that it seems to play a role in malignant megakaryocytopoiesis 59, 60 . Interestingly, we found that the IL-8 and GRO-1 genes were also over-expressed in ET MKs. The possible role of these genes in the malignant megakaryocytopoiesis of ET is unclear. Their production has recently been described in normal MKs 61 and, although the IL-8 cytokine is known to down-regulate proliferation of human myeloid and megakaryocytic progenitor cells 62 , it may also function as an autocrine growth factor and apoptosis resistance factor 63 . The percentages of apoptotic MKs from ET patients were compared with those of healthy subjects after incubation with 0.1, 1, 10 and 100 ng/mL of TPO. Data are expressed as means (standard deviations were always within 6% of the means).
